COVID-19 Treatment with Paxlovid

Primary Benefits: Morbidity and Mortality Reduction

• The World Health Organization strongly recommends Paxlovid for patients with non-severe COVID-19 at high risk of hospitalization, based on high certainty evidence of important reductions in hospitalization and moderate certainty evidence of survival benefit 1
• The World Health Organization recommends Paxlovid due to its greater efficacy and better safety profile compared to molnupiravir 2, 1

Symptom Improvement and Viral Clearance

• Paxlovid may reduce time to symptom resolution, though the evidence is less robust than for hospitalization/mortality outcomes 1
• The primary benefit of Paxlovid is preventing disease progression, not eradicating the virus faster, as it does not meaningfully shorten the time to viral clearance 1

Critical Treatment Window and Patient Selection

• Paxlovid must be initiated within 5 days of symptom onset to be effective, and should be started as early as possible 1, 3
• High-risk patients, including those with immunocompromising conditions 1, chronic medical conditions (cardiovascular disease, diabetes, chronic lung disease, obesity) 4, and unvaccinated or incompletely vaccinated status 1, are most likely to benefit from Paxlovid

Real-World Effectiveness and Long COVID Considerations

• Preliminary evidence suggests Paxlovid may reduce long COVID incidence by 25% when used for acute infection, though this requires further investigation 4
• The World Health Organization recommends against Paxlovid in patients at moderate or low risk of hospitalization, as the benefits do not outweigh potential harms and costs in these populations 5, 3